标题
Are antiangiogenics a good ‘partner’ for immunotherapy in ovarian cancer?
作者
关键词
-
出版物
ANGIOGENESIS
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-07-20
DOI
10.1007/s10456-020-09734-w
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
- (2019) Mary L. Disis et al. JAMA Oncology
- Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
- (2019) Yu Kato et al. PLoS One
- Synthetic lethality guiding selection of drug combinations in ovarian cancer
- (2019) Andreas Heinzel et al. PLoS One
- Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
- (2019) Vicky Makker et al. LANCET ONCOLOGY
- Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer
- (2019) J F Liu et al. ANNALS OF ONCOLOGY
- Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study
- (2019) U A Matulonis et al. ANNALS OF ONCOLOGY
- A phase II trial of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer
- (2019) E. Zsiros et al. GYNECOLOGIC ONCOLOGY
- Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer
- (2018) Lydia Meder et al. CANCER RESEARCH
- An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)
- (2018) Y. Drew et al. GYNECOLOGIC ONCOLOGY
- Nivolumab Plus Erlotinib in Patients With EGFR -Mutant Advanced NSCLC
- (2018) Scott Gettinger et al. Journal of Thoracic Oncology
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)
- (2018) Hendrik‐Tobias Arkenau et al. ONCOLOGIST
- Targeted therapy and immunotherapy for platinum-refractory advanced ovarian adenosquamous carcinoma: a case report
- (2018) Anji Li et al. OncoTargets and Therapy
- Expression of multiple immune checkpoint molecules on T�cells in malignant ascites from epithelial ovarian carcinoma
- (2018) Yuichi Imai et al. Oncology Letters
- TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.
- (2018) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.
- (2018) Sandro Pignata et al. JOURNAL OF CLINICAL ONCOLOGY
- The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy
- (2018) Galaxia Rodriguez et al. Cancers
- 937PDA phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer
- (2018) J F Liu et al. ANNALS OF ONCOLOGY
- Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease
- (2018) Florence T. H. Wu et al. BRITISH JOURNAL OF CANCER
- Roles of the immune system in cancer: from tumor initiation to metastatic progression
- (2018) Hugo Gonzalez et al. GENES & DEVELOPMENT
- Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028
- (2018) Andrea Varga et al. GYNECOLOGIC ONCOLOGY
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
- (2018) J. Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
- (2018) Asim Amin et al. Journal for ImmunoTherapy of Cancer
- Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
- (2018) Isabella Faraoni et al. Cancers
- Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
- (2018) James Chih-Hsin Yang et al. Journal of Thoracic Oncology
- Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis
- (2017) Xia Yuan et al. GYNECOLOGIC ONCOLOGY
- Prognostic value of tumor PD-L1 expression combined with CD8 + tumor infiltrating lymphocytes in high grade serous ovarian cancer
- (2017) Qiaohong Wang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Malignant ascites determine the transmesothelial invasion of ovarian cancer cells
- (2017) Justyna Mikuła-Pietrasik et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
- (2017) Jung-Min Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
- (2017) Jun Zhu et al. Journal of Gynecologic Oncology
- Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
- (2017) Robert L Coleman et al. LANCET ONCOLOGY
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
- (2017) Elizabeth Allen et al. Science Translational Medicine
- Immunological Functions of the Omentum
- (2017) Selene Meza-Perez et al. TRENDS IN IMMUNOLOGY
- Prognostic value of PD –L1 expression in patients with primary solid tumors
- (2017) Xiao Xiang et al. Oncotarget
- Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
- (2017) et al. JAMA Oncology
- The Unique Molecular and Cellular Microenvironment of Ovarian Cancer
- (2017) Thomas Worzfeld et al. Frontiers in Oncology
- Anti-angiogenic agents in ovarian cancer: past, present, and future
- (2016) B. J. Monk et al. ANNALS OF ONCOLOGY
- Ipilimumab and Bevacizumab in Glioblastoma
- (2016) T. Carter et al. CLINICAL ONCOLOGY
- Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2
- (2016) Bradley J. Monk et al. GYNECOLOGIC ONCOLOGY
- Tumor angiogenesis—characteristics of tumor endothelial cells
- (2016) Kyoko Hida et al. International Journal of Clinical Oncology
- A cancer treatment based on synergy between anti-angiogenic and immune cell therapies
- (2016) Luis Soto-Ortiz et al. JOURNAL OF THEORETICAL BIOLOGY
- Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
- (2016) Jonathan A Ledermann et al. LANCET
- Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
- (2016) Andreas du Bois et al. LANCET ONCOLOGY
- The ever-expanding role of HIF in tumour and stromal biology
- (2016) Edward L. LaGory et al. NATURE CELL BIOLOGY
- The Development of an Angiogenic Protein “Signature” in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling
- (2016) Sofia-Paraskevi Trachana et al. PLoS One
- The transcriptional signature of human ovarian carcinoma macrophages is associated with extracellular matrix reorganization
- (2016) Florian Finkernagel et al. Oncotarget
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
- (2016) Kyle C. Strickland et al. Oncotarget
- New Mechanisms of Tumor-Associated Macrophages on Promoting Tumor Progression: Recent Research Advances and Potential Targets for Tumor Immunotherapy
- (2016) Qiujun Guo et al. Journal of Immunology Research
- The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment
- (2016) Shona A. Hendry et al. Frontiers in Immunology
- Targeted attack: mechanisms by which ovarian cancers suppress the immune system
- (2016) Irina V. Tiper et al. Translational Cancer Research
- Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?
- (2016) Yu-Ling Li et al. Cancer Biology & Medicine
- A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213)
- (2015) R.L. Coleman et al. GYNECOLOGIC ONCOLOGY
- Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
- (2015) Carol Aghajanian et al. GYNECOLOGIC ONCOLOGY
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
- (2015) Amit M Oza et al. LANCET ONCOLOGY
- Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
- (2015) Silvia Darb-Esfahani et al. Oncotarget
- T Lymphocyte–Endothelial Interactions: Emerging Understanding of Trafficking and Antigen-Specific Immunity
- (2015) Christopher V. Carman et al. Frontiers in Immunology
- Introduction to managing patients with recurrent ovarian cancer
- (2015) Hani Gabra EJC SUPPLEMENTS
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
- (2014) Andreas du Bois et al. JOURNAL OF CLINICAL ONCOLOGY
- Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine
- (2014) Anna R Kwilas et al. Journal of Translational Medicine
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
- (2014) Joyce F Liu et al. LANCET ONCOLOGY
- Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
- (2014) Bradley J Monk et al. LANCET ONCOLOGY
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis
- (2014) Vladimir Riabov et al. Frontiers in Physiology
- Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
- (2013) Y. Huang et al. CANCER RESEARCH
- Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effectin vivo
- (2013) S. Yasuda et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential
- (2013) S. Banerjee et al. CLINICAL CANCER RESEARCH
- Tumour heterogeneity in the clinic
- (2013) Philippe L. Bedard et al. NATURE
- T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
- (2012) A. Facciabene et al. CANCER RESEARCH
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Basic and Therapeutic Aspects of Angiogenesis
- (2011) Michael Potente et al. CELL
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
- (2010) R. K. Shrimali et al. CANCER RESEARCH
- Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
- (2010) Subhra K Biswas et al. NATURE IMMUNOLOGY
- Chemotherapy and radiotherapy: Cryptic anticancer vaccines
- (2010) Yuting Ma et al. SEMINARS IN IMMUNOLOGY
- The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
- (2008) Takuya Osada et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Fibroblast growth factor regulation of neovascularization
- (2008) Masahiro Murakami et al. CURRENT OPINION IN HEMATOLOGY
- Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy
- (2007) Aristotelis Bamias et al. GYNECOLOGIC ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started